Zhao Yi, Sun Wei, Ji Zhigang, Liu Xiaoyan, Qiao Yi
Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Science, Beijing, China.
School of Basic Medicine, Institute of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Front Oncol. 2023 Mar 3;13:1061083. doi: 10.3389/fonc.2023.1061083. eCollection 2023.
Biomarkers of different stages and grades of bladder cancer (BC) are important in clinical work. The objective of our study was to investigate new biomarkers of early-stage BC with liquid chromatography-high resolution mass spectrometry (LC-HRMS) using serum samples.
A total of 215 cases were included in our study, including 109 healthy adults as the control group and 106 non-muscle invasive bladder cancer (NMIBC) patients as the NMIBC group. Serum samples were collected from BC patients in the early stage, called NMIBC, and healthy people before surgery. We used LC-HRMS to distinguish the NMIBC group from the control group and the low-grade NMIBC group from the control group.
An apparent difference between the NMIBC group and the control group was visualized by unsupervised principal component analysis (PCA). Metabolite panels for 16-hydroxy-10-oxohexadecanoic acid, PGF2a ethanolamide, sulfoglycolithocholate, and threoninyl-alanine were used to distinguish the two groups. The area under the curve (AUC) of the panels was 0.985, and the sensitivity and specificity were 98.63% and 98.59%, respectively. To distinguish the low-grade NMIBC group from the control group, serum metabolic profiling differences between the low-grade NMIBC group and control group samples were also analyzed. Metabolite panels of L-octanoylcarnitine, PGF2a ethanolamide, and threoninyl-alanine showed good discrimination performance. The AUC of the panels was 0.999, and the sensitivity and specificity were 97.8% and 100%, respectively.
Metabolomics analysis of serum samples can distinguish the NMIBC group from the control group, particularly the early-stage low-grade NMIBC group.
膀胱癌（BC）不同阶段和分级的生物标志物在临床工作中很重要。我们研究的目的是使用血清样本，通过液相色谱-高分辨率质谱（LC-HRMS）研究早期BC的新生物标志物。
我们的研究共纳入215例，包括109名健康成年人作为对照组，106例非肌层浸润性膀胱癌（NMIBC）患者作为NMIBC组。在手术前从早期BC患者（即NMIBC）和健康人那里采集血清样本。我们使用LC-HRMS将NMIBC组与对照组区分开，并将低级别NMIBC组与对照组区分开。
通过无监督主成分分析（PCA）可以看到NMIBC组与对照组之间存在明显差异。使用16-羟基-10-氧代十六烷酸、PGF2α乙醇酰胺、磺基甘氨石胆酸和苏氨酰丙氨酸的代谢物面板来区分两组。这些面板的曲线下面积（AUC）为0.985，敏感性和特异性分别为98.63%和98.59%。为了将低级别NMIBC组与对照组区分开，还分析了低级别NMIBC组与对照组样本之间的血清代谢谱差异。L-辛酰肉碱、PGF2α乙醇酰胺和苏氨酰丙氨酸的代谢物面板显示出良好的区分性能。这些面板的AUC为0.999，敏感性和特异性分别为97.8%和100%。
血清样本的代谢组学分析可以区分NMIBC组与对照组，特别是早期低级别NMIBC组。
